Get the Stockscreener App
18.14
25.96%
-6.36
After Hours:
18.59
0.45
+2.48%
Lenz Therapeutics Inc stock is traded at $18.14, with a volume of 6.62M.
It is down -25.96% in the last 24 hours and down -28.86% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$24.50
Open:
$24.66
24h Volume:
6.62M
Relative Volume:
6.20
Market Cap:
$567.60M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-3.2408
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
-32.11%
1M Performance:
-28.86%
6M Performance:
-38.67%
1Y Performance:
-41.07%
1-Day Range:
$15.70
$24.79
1-Week Range:
$15.70
$27.84
52-Week Range:
$15.70
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
18.14 | 766.60M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
LENZ Therapeutics (NASDAQ:LENZ) Sees Large Volume IncreaseShould You Buy? - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year LowShould You Sell? - MarketBeat
LENZ Therapeutics Responds to FDA Adverse Event Report - TipRanks
LENZ Therapeutics Addresses Adverse Event Report - TradingView — Track All Markets
Lenz plunges after adverse event report on eye therapy - MSN
ABBV Stock News: Lenz Therapeutics Faces Setback with FDA Report - GuruFocus
LENZ plunges after adverse event report on eye therapy - Seeking Alpha
Stempoint Capital LP Buys Shares of 183,912 LENZ Therapeutics, Inc. $LENZ - MarketBeat
No Need For Reading Glasses? Vizz Eye Drop That Improves Near Vision Has FDA Nod - MSN
LENZ Therapeutics (LENZ) Receives a Buy from Citi - The Globe and Mail
Stock Analysis: Will LENZ Therapeutics Inc stock rally after Fed decisionsWeekly Investment Summary & Long-Term Safe Investment Ideas - BỘ NỘI VỤ
Saturn V Capital Management LP Invests $10.03 Million in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Will LENZ Therapeutics Inc. stock gain from strong economyJuly 2025 Highlights & Smart Swing Trading Alerts - Newser
Transcript : LENZ Therapeutics, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-04-2025 10 - marketscreener.com
Lenz Therapeutics: A Close Look (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 6.1%Here's What Happened - MarketBeat
Skandinaviska Enskilda Banken AB publ Acquires New Stake in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Geode Capital Management LLC Grows Stock Position in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ - Ophthalmology Times
Leadership: Lenz Therapeutics CEO gives people autonomy and responsibility - MSN
Lenz Therapeutics, Lotus Pharmaceutical Say New Drug Application for Presbyopia Treatment Submitted in South Korea - marketscreener.com
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia - The Manila Times
LENZ Therapeutics and Lotus Pharmaceutical Submit New Drug Application for VIZZ in South Korea to Treat Presbyopia - Quiver Quantitative
LENZ Therapeutics (Nasdaq: LENZ) logs 2nd ex-US VIZZ filing, up to $125 million milestones - Stock Titan
LENZ Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Piper Sandler 37th Annual Healthcare Conference - LENZ Therapeutics
LENZ Therapeutics (Nasdaq: LENZ) to webcast three December investor conferences - Stock Titan
LENZ Therapeutics (NASDAQ:LENZ) Insider Shawn Olsson Sells 10,000 Shares - MarketBeat
Building trade automation scripts for LENZ Therapeutics Inc.July 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
Ranking LENZ Therapeutics Inc. among high performing stocks via toolsEarnings Recap Summary & Short-Term High Return Strategies - newser.com
Olsson, Lenz therapeutics CCO, sells $261k in stock By Investing.com - Investing.com South Africa
How LENZ Therapeutics Inc. stock reacts to oil prices2025 Price Targets & High Return Stock Watch Alerts - newser.com
Olsson, Lenz therapeutics CCO, sells $261k in stock - Investing.com
LENZ Therapeutics CCO Shawn Olsson Sells 10,000 Shares - TradingView
Officer Olsson Sells 10,000 ($261K) Of LENZ Therapeutics Inc [LENZ] - TradingView
Is LENZ Therapeutics Inc. stock a buy in volatile marketsWeekly Profit Recap & Weekly Breakout Watchlists - newser.com
Signal strength of LENZ Therapeutics Inc. stock in tech scannersJuly 2025 Institutional & Weekly Stock Performance Updates - newser.com
How LENZ Therapeutics Inc. stock reacts to Fed rate cutsEarnings Risk Report & Technical Confirmation Alerts - newser.com
Is LENZ Therapeutics Inc. stock a dividend growth opportunityJuly 2025 Levels & Stepwise Entry and Exit Trade Signals - newser.com
Combining price and volume data for LENZ Therapeutics Inc.Trade Ideas & Stepwise Trade Signal Implementation - newser.com
Can LENZ Therapeutics Inc. stock maintain operating marginsRate Hike & Precise Swing Trade Entry Alerts - newser.com
Tools to assess LENZ Therapeutics Inc.’s risk profileWeekly Earnings Recap & Low Drawdown Trading Techniques - newser.com
Candriam S.C.A. Takes $5.02 Million Position in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):